Fiche du document
24 janvier 2025
- 10938/25144
- 31614561.0
- 2-s2.0-85073441026
Ce document est lié à :
Biomolecules
Mots-clés
Antimicrobial peptides Bacterial resistance Clinical strain Helicobacter pylori Human gastric explant Temporin-sha Anti-bacterial agents Antimicrobial cationic peptides Cell membrane permeability Humans Mass spectrometry Microbial sensitivity tests Alanine Glycine Pepsin a Polypeptide antibiotic agent Stomach mucin Temporin sha Temporin sha g10a Temporin sha g4,7,10a Temporin sha g4,7a Temporin sha g4a Temporin sha g7,10a Temporin sha g7a Unclassified drug Antiinfective agent Antimicrobial cationic peptide Temporin Article Bacterial strain Bactericidal activity Controlled study Gastric cell line Human Human cell Human tissue Nonhuman Stomach tissue Chemistry Drug effect Growth, development and aging Microbial sensitivity test SynthesisSujets proches
Campylobacter pyloriCiter ce document
Olleik et al., « Temporin-SHa and its analogs as potential candidates for the treatment of helicobacter pylori », American University of Beirut ScholarWorks
Partage / Export
Résumé
Helicobacter pylori is one of the most prevalent pathogens colonizing 50% of the world's population and causing gastritis and gastric cancer. Even with triple and quadruple antibiotic therapies, H. pylori shows increased prevalence of resistance to conventional antibiotics and treatment failure. Due to their pore-forming activity, antimicrobial peptides (AMP) are considered as a good alternative to conventional antibiotics, particularly in the case of resistant bacteria. In this study, temporin-SHa (a frog AMP) and its analogs obtained by Gly to Ala substitutions were tested against H. pylori. Results showed differences in the antibacterial activity and toxicity of the peptides in relation to the number and position of D-Ala substitution. Temporin-SHa and its analog NST1 were identified as the best molecules, both peptides being active on clinical resistant strains, killing 90–100% of bacteria in less than 1 h and showing low to no toxicity against human gastric cells and tissue. Importantly, the presence of gastric mucins did not prevent the antibacterial effect of temporin-SHa and NST1, NST1 being in addition resistant to pepsin. Taken together, our results demonstrated that temporin-SHa and its analog NST1 could be considered as potential candidates to treat H. pylori, particularly in the case of resistant strains. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.
